Analysis of the cerebrospinal fluid can detect whether a person has Alzheimer’s disease before symptoms appear. Researchers at the Sahlgrenska Academy have studied biomarkers that offer more reliable diagnosis and, in the longer term, the possibility of effective new treatments.
